(Q33427744)

English

Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

phase III clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Isabelle Ray-Coquard

3

object named as

Isabelle Ray-Coquard

0 references

object named as

Sandro Pignata

5

0 references

8

object named as

Ignace Vergote

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Mariusz Bidziński

15

object named as

Mariusz Bidziński

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Giovanni Scambia

20

object named as

Giovanni Scambia

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

18

object named as

Felix Hilpert

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Andreas du Bois

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Gunnar Kristensen

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Alexander Reuss

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Nicoletta Colombo

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Ursula Denison

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jose M Del Campo

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Petronella Ottevanger

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Martin Heubner

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Thomas Minarik

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Emmanuel Sevin

13

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Nikolaus de Gregorio

14

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jacobus Pfisterer

16

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Susanne Malander

17

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Mansoor R Mirza

19

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Werner Meier

21

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Maria O Nicoletto

22

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Line Bjørge

23

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Alain Lortholary

24

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Martin Oliver Sailer

25

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Michael Merger

26

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Philipp Harter

27

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

AGO Study Group led Gynecologic Cancer Intergroup/European Network of Gynaecologic Oncology Trials Groups Intergroup Consortium

28

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

13 November 2015

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

17

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

78-89

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900366-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900366-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival for ovarian cancer in Europe: the across-country variation did not shrink in the past decade

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900366-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900366-6

7 January 2021

based on heuristic

inferred from DOI database lookup

2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900366-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900366-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900366-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900366-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900366-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer S

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900366-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III Trial of Carboplatin Plus Paclitaxel With or Without Gemcitabine in First-Line Treatment of Epithelial Ovarian Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900366-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900366-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900366-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900366-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900366-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeting angiogenesis in gynecologic cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900366-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Incorporation of bevacizumab in the primary treatment of ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900366-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase 3 trial of bevacizumab in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900366-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900366-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Bevacizumab in the treatment of ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900366-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Incorporation of pazopanib in maintenance therapy of ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900366-6

7 January 2021

based on heuristic

inferred from DOI database lookup

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900366-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900366-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900366-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900366-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Small sample inference for fixed effects from restricted maximum likelihood.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900366-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900366-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900366-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900366-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(15)00366-6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33427744&oldid=2046290129"